|
Post by EveningOfTheDay on Nov 30, 2014 14:36:05 GMT -5
I also find this interesting,
"Self-injectable and other high technology drugs which are newly approved by the Food and Drug Administration (FDA) are automatically placed on the Tier 4 drug copayment level."
I assume, although assumption is the mother of all mistakes, that insulin pens are considered self injectables. If so this would seem to indicate that all forms of handrail insulin started in Tier 4 and worked their way down to were they are now, Tier 2.
|
|
|
Post by ashiwi on Nov 30, 2014 14:39:15 GMT -5
|
|
|
Post by EveningOfTheDay on Nov 30, 2014 14:51:50 GMT -5
Thanks, that is a great link. I see Novolog (36) and Humalog (42) are among the top 50. If Afrezza can make the list in the first year we are up to a great start.
|
|
|
Post by ezrasfund on Nov 30, 2014 21:22:53 GMT -5
Thanks, that is a great link. I see Novolog (36) and Humalog (42) are among the top 50. If Afrezza can make the list in the first year we are up to a great start. But also NovoLog FlexPen #34 and Humalog KwikPen #69 would combine to put them both nearer the top; about $710 million for Novolog in both forms which would be #14. Combined Lantus and Lantus Solostar are over $1.5 Billion (that's for 3 months) and would put them as the 4th best selling drug. But as you scan down the list Sanofi does not appear again in the top 100. Don't you think they need Afrezza to be a blockbuster?
|
|
|
Post by babaoriley on Nov 30, 2014 23:06:09 GMT -5
Brentie, is one cat performing a pelvic on the other in your latest Avatar? Is that an FDA approved procedure and, if so, into what tier does it fall?
And by the way, thanks to all who have participated so far in this very important issue of how and where Afrezza may be placed - in box seats (available mainly to the privileged) or the bleachers (available to everyone who needs it). The beer tastes a lot better in the bleachers!
|
|